Your browser doesn't support javascript.
loading
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
Ho, William W; Gomes-Santos, Igor L; Aoki, Shuichi; Datta, Meenal; Kawaguchi, Kosuke; Talele, Nilesh P; Roberge, Sylvie; Ren, Jun; Liu, Hao; Chen, Ivy X; Andersson, Patrik; Chatterjee, Sampurna; Kumar, Ashwin S; Amoozgar, Zohreh; Zhang, Qixian; Huang, Peigen; Ng, Mei Rosa; Chauhan, Vikash P; Xu, Lei; Duda, Dan G; Clark, Jeffrey W; Pittet, Mikael J; Fukumura, Dai; Jain, Rakesh K.
Afiliación
  • Ho WW; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Gomes-Santos IL; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Aoki S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Datta M; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Kawaguchi K; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Talele NP; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Roberge S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Ren J; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Liu H; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Chen IX; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Andersson P; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Chatterjee S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Kumar AS; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Amoozgar Z; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Zhang Q; Harvard-MIT Program in Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Huang P; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Ng MR; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Chauhan VP; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Xu L; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Duda DG; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Clark JW; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Pittet MJ; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Fukumura D; Department of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Jain RK; Department of Pathology and Immunology, University of Geneva, CH-1211 Geneva, Switzerland; mikael.pittet@unige.ch dai@steele.mgh.harvard.edu jain@steele.mgh.harvard.edu.
Proc Natl Acad Sci U S A ; 118(45)2021 11 09.
Article en En | MEDLINE | ID: mdl-34725151
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Inhibidores de Puntos de Control Inmunológico / Neoplasias Hepáticas Experimentales Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Inhibidores de Puntos de Control Inmunológico / Neoplasias Hepáticas Experimentales Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article